Aflibercept

Chemical formula: C₄₃₁₈H₆₇₈₈N₁₁₆₄O₁₃₀₄S₃₂ Molecular mass: 115,000 g/mol

Therapeutic indications

Aflibercept is indicated for:

Metastatic colorectal cancer (MCRC)

Population group: only adults (18 years old or older)

Aflibercept in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

4 mg/kg once every 2 weeks

Neovascular (wet) age-related macular degeneration (AMD)

Population group: only adults (18 years old or older)

Exudative age-related macular degeneration

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month

Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)

Population group: only adults (18 years old or older)

Thrombosis of retinal vein and additionally Macular retinal edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month

Visual impairment due to diabetic macular oedema (DME)

Population group: only adults (18 years old or older)

Diabetic macular edema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once every month for five consecutive doses, followed by 2 mg every two months

Visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Population group: only adults (18 years old or older)

mCNV - myopic choroidal neovascularisation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2 mg once

Retinopathy of prematurity (ROP) with zone I, zone II or AP-ROP disease

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old)

Aflibercept is indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.4 mg as a single injection per eye with the possibility of one more dose within 6 months

Contraindications

Aflibercept is contraindicated in the following cases:

Ocular, periocular, intraocular inflammation or infection

Ophthalmitis

Major surgery

Surgical procedure

Lactation - Intravenous administration

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈